Audentes Therapeutics, Inc.
CIK 0001628738
Revenue (TTM)
—
Q3 Nov 2019
Net Income (TTM)
−$176.19M
+1.9% YoY
Q3 Nov 2019
EPS Diluted (TTM)
—
Q3 Nov 2019
Gross Margin
—
Q3 Nov 2019
Operating Margin
—
Q3 Nov 2019
Net Margin
—
Q3 Nov 2019
Free Cash Flow (TTM)
−$113.08M
Q3 Nov 2019
Cash
$63.59M
Q3 Nov 2019
Total Debt
—
Q3 Nov 2019
Shares Outstanding
45.78M sh
Q3 Nov 2019
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.